John Magenau is a Hematology physician. OpenAlex indexes 148 publications with 7,089 citations (h-index 28); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 E Medical Center Dr
Ann Arbor, MI 481095000
Telephone
734-936-4000Provider last certified this registry record 23 Nov 2020.
Clinical trials
- Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome
Sponsor: University of Michigan Rogel Cancer Center
- Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab
Sponsor: University of Michigan Rogel Cancer Center
- Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia
Sponsor: University of Michigan Rogel Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- CSL BehringProgram year20216 payments
- Gilead Sciences, Inc.Program year20212 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2017–2021 per NIH RePORTER. The latest:
- Targeting antigen cross-presentation to enhance anti-leukemic responses after allogeneic transplantation
University of Michigan at Ann Arbor
FY2021$196,560K23AI123595 - Targeting antigen cross-presentation to enhance anti-leukemic responses after allogeneic transplantation
University of Michigan at Ann Arbor
FY2020$196,560K23AI123595 - Targeting antigen cross-presentation to enhance anti-leukemic responses after allogeneic transplantation
University of Michigan at Ann Arbor
FY2019$196,560K23AI123595
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Cardiovascular Risk Stratification of Patients Undergoing Hematopoietic Stem Cell Transplantation: The CARE‐BMT Risk Score
Journal of the American Heart Association
2023 - NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022
Journal of the National Comprehensive Cancer Network
2023
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Joseph Antin, MD
Harvard University
Scott Kaufmann, MD
Mayo Clinic College of Medicine
Jeffrey Miller, MD
University of Minnesota Medical School
Ruben Mesa, MD
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”